P1070 / EFV in HIV-infected and HIV/TB Co-infected Subjects

P1070 is a Phase I, dose-finding study of efavirenz among HIV-infected and HIV/TB co-infected infants and children who live in low and middle income countries and who are eligible for ARV treatment.  The study is designed to determine genotypic specific dose requirements of EFV administered as opened capsules that provide systemic exposure similar to that which has been shown to be safe and effective in older children and adults, determine 24-week safety and tolerance of EFV-based HAART, and explore genetic polymorphisms as contributing sources of variability in EFV exposure and metabolism.